Letter to the editor regarding article, “Role of glycogen synthase kinase following myocardial infarction and ischemia–reperfusion”

Source: Apoptosis - Category: Molecular Biology Source Type: research

Related Links:

BOSTON (CBS) — TPA is a drug that is used to help stroke and heart attack victims. It works by breaking up or busting blood clots. Doctors at Beth Israel Deaconess Medical Center are now using it in a clinical trial on gravely ill coronavirus patients. “There’s a lot of very small blood clots accumulating in the lungs of these patients,” said Dr. Christopher Barrett. “And that seems to be at least contributory, if not the predominant reason, that their respiratory failure is so bad.” Dr. Barrett says TPA could help patients recover faster, free up ventilators and even prevent people from...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Syndicated Local Cheryl Fiandaca Coronavirus Health News Source Type: news
Authors: Song Z, Gao R, Yan B Abstract Cardiovascular disease is still the main cause of morbidity and mortality worldwide. Currently, the frontier of research into cardiovascular disease is the field of non-coding RNA. In this review, information was collected on the use of micro-RNAs as non-invasive biomarkers and their role in pathophysiological processes and therapeutic applications. In the case of microRNA-1 and microRNA-133, the roles and regulatory mechanisms of them are reviewed for arrhythmia, myocardial infarction, diabetic cardiomyopathy, myocardial hypertrophy, cardiomyocyte differentiation, and cell re...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research
Authors: Liu Y, Zeng Z, Yu X, Li T, Yao Y, Chen R, Zheng J Abstract The purpose of this study is to investigate the effect of lipoprotein(a) level on long-range prognosis after Percutaneous Coronary Intervention (PCI) in patients with low-density lipoprotein cholesterol (LDL-C) goal attainment. In this retrospective study, 350 patients in Coronary artery disease (CAD) with LDL-C less than 1.8 mmol/L were enrolled in the Guangdong Institute of Cardiovascular Diseases from January 2011 to December 2013. Follow-up was 1 year after PCI. According to the median value of the study population based on Lp(a), the patients ...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research
Authors: Chen E, Cai W, Hu D, Chen L Abstract Remote ischemic conditioning is usually associated with cardioprotective intervention against ischemia-reperfusion. However, the effect of remote ischemic preconditioning (RIC-pre) completed before myocardial reperfusion with intermittent limb ischemia-reperfusion in patients with STEMI undergoing primary percutaneous coronary intervention (PPCI) is unclear. PubMed, EMBASE, and the Cochrane Library were fully searched from the beginning of each database up to September 2019 to find seven RCTs, a total of 2796 patients with STEMI undergoing PPCI with RIC-pre and 2818 pat...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Tags: Rev Cardiovasc Med Source Type: research
This study aimed to ascertain whether tiotropium/olodaterol (T/O) 5/5 μg fixed-dose combination (FDC) may modulate the risk of main cardiovascular outcomes in COPD patients enrolled in randomized controlled trials (RCTs). A meta-analysis (CRD42017070100) was performed by selecting RCTs reporting raw data from the ClinicalTrials.gov database concerning the impact of T/O 5/5 µg FDC vs. monocomponents on the occurrence of specific cardiovascular serious adverse events: arrhythmia, heart failure, myocardial infarction, and stroke. Data were reported as relative risk and 95% Confidence Interval, and the r...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
In the fall of 2019, my hospital put out word that it was looking for physicians who might wish to undergo intensive training to become certified health and wellness coaches. Having worked with patients who have used health coaching, I jumped at the chance. Their experiences were almost universally positive: many of them had attained health goals that had been otherwise elusive, such as the weight loss they invoked annually — and fruitlessly — as a New Year’s resolution. The few physicians I knew who were also coaches seemed to be able to fuse the different skill sets in a way that expanded their ability ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Behavioral Health Exercise and Fitness Healthy Eating Mind body medicine Nutrition Prevention Stress Source Type: blogs
Conclusion: Cerebral aneurysm coiling could be considered as the first choice of treatment in the case of acute MI with hemodynamic stability, before carrying out cardiac endovascular intervention or antiplatelet medication to reduce the risk of rebleeding from a brain aneurysm. PMID: 32257575 [PubMed - as supplied by publisher]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
We carefully read with interest the recent article by Zhao et al. [1] concerning “Circulating Serpina3 levels predict the major adverse cardiac events in patients with myocardial infarction”. This suggests that serine proteinase inhibitor A3 (Serpina3), also called alpha-1antichymotrypsin, may be a powerful prognostic biomarker for major adverse cardiovascular events in pati ents with acute myocardial infarction (MI). Although the exact mechanism is still unclear, this finding means that inhibition of Serpina3 may act as a potential therapeutic strategy for myocardial ischemia/reperfusion (I/R) injury heart.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research
The management of stable ischaemic heart disease continues to evolve with the recently presented ISCHEMIA trial demonstrating that revascularisation therapy (primarily percutaneous coronary intervention, PCI) does not reduce the risk of major adverse cardiac events in high risk stable angina patients with moderate-severe ischaemia [1]. Indeed, the ISCHEMIA trial reported more acute myocardial infarction (AMI) in the first 6  months after randomisation amongst those managed with PCI therapy as compared to those treated with optimal medical therapy alone.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
CONCLUSIONS: In patients with STEMI and MVD, FFR-guided complete revascularization is more beneficial in terms of outcome and health-care costs compared to IRA-only revascularization at 36 months. PMID: 32250250 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
More News: Heart Attack | Molecular Biology